{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:56:13Z","timestamp":1788216973849,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404140"],"award-info":[{"award-number":["82404140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13502-5","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T09:45:30Z","timestamp":1754387130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Meng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"13502_CR1","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.berh.2021.101694","volume":"35","author":"C Stober","year":"2021","unstructured":"Stober, C. Pathogenesis of psoriatic arthritis. Best Pract. Res. Clin. Rheumatol. 35, 101694. https:\/\/doi.org\/10.1016\/j.berh.2021.101694 (2021).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"13502_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale, D. J. & Fearon, U. The pathogenesis of psoriatic arthritis. Lancet 391, 2273\u20132284. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4 (2018).","journal-title":"Lancet"},{"key":"13502_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"A-M Orbai","year":"2017","unstructured":"Orbai, A.-M. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann. Rheum. Dis. 76, 673\u2013680. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210242 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s40744-024-00722-w","volume":"11","author":"X Michelena","year":"2024","unstructured":"Michelena, X. et al. How are we addressing axial psoriatic arthritis in clinical practice?. Rheumatol. Ther. 11, 1441\u20131456. https:\/\/doi.org\/10.1007\/s40744-024-00722-w (2024).","journal-title":"Rheumatol. Ther."},{"key":"13502_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83, 706\u2013719. https:\/\/doi.org\/10.1136\/ard-2024-225531 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR6","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","volume":"4","author":"MLM Mulder","year":"2022","unstructured":"Mulder, M. L. M. et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): A double-blind, placebo-controlled, randomised, trial. Lancet Rheumatol. 4, e252\u2013e261. https:\/\/doi.org\/10.1016\/S2665-9913(22)00028-5 (2022).","journal-title":"Lancet Rheumatol."},{"key":"13502_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli, M. et al. Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story. Ann. Rheum. Dis. 83, 139\u2013160. https:\/\/doi.org\/10.1136\/ard-2023-223850 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki, R. et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br. J. Dermatol. 172, 244\u2013252. https:\/\/doi.org\/10.1111\/bjd.13343 (2015).","journal-title":"Br. J. Dermatol."},{"key":"13502_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter, A. et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J. Eur. Acad. Dermatol. Venereol. 30, 1148\u20131158. https:\/\/doi.org\/10.1111\/jdv.13611 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"13502_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease, P. J. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 76, 79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40259-016-0197-y","volume":"30","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Certolizumab pegol: A review in inflammatory autoimmune diseases. BioDrugs 30, 607\u2013617 (2016).","journal-title":"BioDrugs"},{"key":"13502_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/1744666X.2020.1713754","volume":"16","author":"M Esposito","year":"2020","unstructured":"Esposito, M. et al. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Rev. Clin. Immunol. 16, 119\u2013128. https:\/\/doi.org\/10.1080\/1744666X.2020.1713754 (2020).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"13502_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14712598.2017.1283401","volume":"17","author":"A Campanati","year":"2017","unstructured":"Campanati, A. et al. Certolizumab pegol for the treatment of psoriasis. Expert Opin. Biol. Ther. 17, 387\u2013394. https:\/\/doi.org\/10.1080\/14712598.2017.1283401 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"13502_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","volume":"28","author":"G Pasut","year":"2014","unstructured":"Pasut, G. Pegylation of biological molecules and potential benefits: Pharmacological properties of certolizumab pegol. BioDrugs 28, 15\u201323. https:\/\/doi.org\/10.1007\/s40259-013-0064-z (2014).","journal-title":"BioDrugs"},{"key":"13502_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","volume":"41","author":"EHS Choy","year":"2002","unstructured":"Choy, E. H. S. et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41, 1133\u20131137. https:\/\/doi.org\/10.1093\/rheumatology\/41.10.1133 (2002).","journal-title":"Rheumatology"},{"key":"13502_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/imt-2023-0058","volume":"16","author":"M Tokuyama","year":"2024","unstructured":"Tokuyama, M. & Mabuchi, T. Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment. Immunotherapy 16, 273\u2013285. https:\/\/doi.org\/10.2217\/imt-2023-0058 (2024).","journal-title":"Immunotherapy"},{"key":"13502_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40262-024-01370-7","volume":"63","author":"J van Gendt","year":"2024","unstructured":"van Gendt, J. et al. Pharmacokinetics of monoclonal antibodies throughout pregnancy: A systematic literature review. Clin. Pharmacokinet. 63, 589\u2013622. https:\/\/doi.org\/10.1007\/s40262-024-01370-7 (2024).","journal-title":"Clin. Pharmacokinet."},{"key":"13502_CR18","doi-asserted-by":"publisher","unstructured":"Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 4. https:\/\/doi.org\/10.1136\/rmdopen-2017-000582corr1 (2018).","DOI":"10.1136\/rmdopen-2017-000582corr1"},{"key":"13502_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"13502_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer, A. et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 83, 760\u2013774. https:\/\/doi.org\/10.1136\/ard-2024-225534 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR21","doi-asserted-by":"publisher","first-page":"1169327","DOI":"10.3389\/fphar.2023.1169327","volume":"14","author":"M Li","year":"2023","unstructured":"Li, M., You, R., Su, Y., Zhou, H. & Gong, S. Characteristic analysis of adverse reactions of five anti-TNF\u0251 agents: A descriptive analysis from WHO-VigiAccess. Front. Pharmacol. 14, 1169327. https:\/\/doi.org\/10.3389\/fphar.2023.1169327 (2023).","journal-title":"Front. Pharmacol."},{"key":"13502_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","volume":"18","author":"C Chen","year":"2019","unstructured":"Chen, C., Borrego, M. E., Roberts, M. H. & Raisch, D. W. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi\u2019s) used in treatment of autoimmune diseases. Expert Opin. Drug. Saf. 18, 733\u2013744. https:\/\/doi.org\/10.1080\/14740338.2019.1630063 (2019).","journal-title":"Expert Opin. Drug. Saf."},{"key":"13502_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","volume":"16","author":"Y-M Chiu","year":"2020","unstructured":"Chiu, Y.-M. & Chen, D.-Y. Infection risk in patients undergoing treatment for inflammatory arthritis: Non-biologics versus biologics. Expert Rev. Clin. Immunol. 16, 207\u2013228. https:\/\/doi.org\/10.1080\/1744666X.2019.1705785 (2020).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"13502_CR24","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","volume":"111","author":"H Liu","year":"2025","unstructured":"Liu, H., Yang, Q., Li, Z., Yan, S. & Ming, S. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int. J. Surg. 111, 1988\u20131994. https:\/\/doi.org\/10.1097\/JS9.0000000000002194 (2025).","journal-title":"Int. J. Surg."},{"key":"13502_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","volume":"154","author":"H Chen","year":"2024","unstructured":"Chen, H., Yang, G. & Ma, J. Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database. Int. J. Cancer 154, 1616\u20131625. https:\/\/doi.org\/10.1002\/ijc.34848 (2024).","journal-title":"Int. J. Cancer"},{"key":"13502_CR26","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","volume":"15","author":"K Zhao","year":"2024","unstructured":"Zhao, K., Zhao, Y., Xiao, S. & Tu, C. Assessing the real-world safety of tralokinumab for atopic dermatitis: Insights from a comprehensive analysis of FAERS data. Front. Pharmacol. 15, 1458438. https:\/\/doi.org\/10.3389\/fphar.2024.1458438 (2024).","journal-title":"Front. Pharmacol."},{"key":"13502_CR27","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-024-55185-4","volume":"14","author":"H Su","year":"2024","unstructured":"Su, H., Jia, J., Mao, Y., Zhu, R. & Li, Z. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins. Sci. Rep. 14, 5095. https:\/\/doi.org\/10.1038\/s41598-024-55185-4 (2024).","journal-title":"Sci. Rep."},{"key":"13502_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"13502_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"13502_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ph14010004","volume":"14","author":"Y Noguchi","year":"2020","unstructured":"Noguchi, Y., Aoyama, K., Kubo, S., Tachi, T. & Teramachi, H. Improved detection criteria for detecting drug-drug interaction signals using the proportional reporting ratio. Pharmaceuticals 14, 4. https:\/\/doi.org\/10.3390\/ph14010004 (2020).","journal-title":"Pharmaceuticals"},{"key":"13502_CR31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","volume":"76","author":"K Tada","year":"2020","unstructured":"Tada, K., Maruo, K., Isogawa, N., Yamaguchi, Y. & Gosho, M. Borrowing external information to improve Bayesian confidence propagation neural network. Eur. J. Clin. Pharmacol. 76, 1311\u20131319. https:\/\/doi.org\/10.1007\/s00228-020-02909-w (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"13502_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda, T., Kadoyama, K., Minami, K. & Okuno, Y. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int. J. Med. Sci. 11, 461\u2013465. https:\/\/doi.org\/10.7150\/ijms.7967 (2014).","journal-title":"Int. J. Med. Sci."},{"key":"13502_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"13502_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate, A. Bayesian confidence propagation neural network. Drug Saf. 30, 623\u2013625. https:\/\/doi.org\/10.2165\/00002018-200730070-00011 (2007).","journal-title":"Drug Saf."},{"key":"13502_CR35","doi-asserted-by":"publisher","first-page":"1518258","DOI":"10.3389\/fphar.2025.1518258","volume":"16","author":"H Teng","year":"2025","unstructured":"Teng, H., Zhang, S., Yu, J. & Li, F. Adverse event profile differences between maribavir and valganciclovir: Findings from the FDA adverse event reporting system. Front. Pharmacol. 16, 1518258. https:\/\/doi.org\/10.3389\/fphar.2025.1518258 (2025).","journal-title":"Front. Pharmacol."},{"key":"13502_CR36","doi-asserted-by":"publisher","first-page":"e0324675","DOI":"10.1371\/journal.pone.0324675","volume":"20","author":"C Zhang","year":"2025","unstructured":"Zhang, C., Wen, J. & Li, Y. A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS). PLoS ONE 20, e0324675. https:\/\/doi.org\/10.1371\/journal.pone.0324675 (2025).","journal-title":"PLoS ONE"},{"key":"13502_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.12385","volume":"38","author":"P Deepak","year":"2013","unstructured":"Deepak, P., Stobaugh, D. J., Sherid, M., Sifuentes, H. & Ehrenpreis, E. D. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol. Ther. 38, 388\u2013396. https:\/\/doi.org\/10.1111\/apt.12385 (2013).","journal-title":"Aliment Pharmacol. Ther."},{"key":"13502_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","volume":"78","author":"S Glatt","year":"2019","unstructured":"Glatt, S. et al. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: A proof-of-concept study. Ann. Rheum. Dis. 78, 1033\u20131040. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214943 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR40","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","volume":"2011","author":"JA Singh","year":"2011","unstructured":"Singh, J. A. et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011, CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"13502_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-017-1496-5","volume":"20","author":"LR Harrold","year":"2018","unstructured":"Harrold, L. R. et al. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: Data from a national U.S. rheumatoid arthritis registry. Arthritis Res. Ther. 20, 2. https:\/\/doi.org\/10.1186\/s13075-017-1496-5 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"13502_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk, V. P. et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: An integrated analysis from clinical trials. Ann. Rheum. Dis. 74, 96\u2013103. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203660 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"13502_CR43","doi-asserted-by":"publisher","first-page":"103332","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano, L. et al. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun. Rev. 22, 103332. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332 (2023).","journal-title":"Autoimmun. Rev."},{"key":"13502_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3238\/arztebl.m2022.0067","volume":"119","author":"I Kremenevski","year":"2022","unstructured":"Kremenevski, I., Sander, O., Sticherling, M., Raithel, M. & LastName, F. M. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch. Arztebl. Int. 119, 88\u201395. https:\/\/doi.org\/10.3238\/arztebl.m2022.0067 (2022).","journal-title":"Dtsch. Arztebl. Int."},{"key":"13502_CR45","first-page":"1","volume":"26","author":"J Strain","year":"2021","unstructured":"Strain, J., Leis, M., Lee, K. O. & Fleming, P. Certolizumab pegol in plaque psoriasis: Considerations for pregnancy. Skin Therapy Lett. 26, 1\u20135 (2021).","journal-title":"Skin Therapy Lett."},{"key":"13502_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jbspin.2016.03.014","volume":"84","author":"A Hoxha","year":"2017","unstructured":"Hoxha, A. et al. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Jt. Bone Spine 84, 169\u2013173. https:\/\/doi.org\/10.1016\/j.jbspin.2016.03.014 (2017).","journal-title":"Jt. Bone Spine"},{"key":"13502_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer, C. et al. Pregnancy outcome after TNF-\u03b1 inhibitor therapy during the first trimester: A prospective multicentre cohort study. Br. J. Clin. Pharmacol. 80, 727\u2013739. https:\/\/doi.org\/10.1111\/bcp.12642 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"13502_CR48","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/art.40508","volume":"70","author":"MEB Clowse","year":"2018","unstructured":"Clowse, M. E. B. et al. Pregnancy outcomes after exposure to certolizumab pegol: Updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 70, 1399\u20131407. https:\/\/doi.org\/10.1002\/art.40508 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"13502_CR49","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3899\/jrheum.140189","volume":"42","author":"MEB Clowse","year":"2015","unstructured":"Clowse, M. E. B. et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 42, 2270\u20132278. https:\/\/doi.org\/10.3899\/jrheum.140189 (2015).","journal-title":"J Rheumatol"},{"key":"13502_CR50","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ph17070904","volume":"17","author":"M Gaio","year":"2024","unstructured":"Gaio, M. et al. Pregnancy recommendations solely based on preclinical evidence should be integrated with real-world evidence: A disproportionality analysis of certolizumab and other TNF-alpha inhibitors used in pregnant patients with psoriasis. Pharmaceuticals 17, 904 (2024).","journal-title":"Pharmaceuticals"},{"key":"13502_CR51","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis, J. R. et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: A pooled analysis of 11 317 patients across clinical trials. RMD Open 5, e000942. https:\/\/doi.org\/10.1136\/rmdopen-2019-000942 (2019).","journal-title":"RMD Open"},{"key":"13502_CR52","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"P Diak","year":"2010","unstructured":"Diak, P. et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62, 2517\u20132524. https:\/\/doi.org\/10.1002\/art.27511 (2010).","journal-title":"Arthritis Rheum."},{"key":"13502_CR53","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal, B. B. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 3, 745\u2013756 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"13502_CR54","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1126\/science.1071924","volume":"296","author":"G Chen","year":"2002","unstructured":"Chen, G. & Goeddel, D. V. TNF-R1 signaling: A beautiful pathway. Science 296, 1634\u20131635 (2002).","journal-title":"Science"},{"key":"13502_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.immuni.2004.10.001","volume":"21","author":"JR Muppidi","year":"2004","unstructured":"Muppidi, J. R., Tschopp, J. & Siegel, R. M. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21, 461\u2013465 (2004).","journal-title":"Immunity"},{"key":"13502_CR56","first-page":"539","volume":"140","author":"LF Fajardo","year":"1992","unstructured":"Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D. & Allison, A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 140, 539\u2013544 (1992).","journal-title":"Am. J. Pathol."},{"key":"13502_CR57","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1046\/j.1523-1755.1999.00483.x","volume":"55","author":"L Borghi","year":"1999","unstructured":"Borghi, L. et al. Essential arterial hypertension and stone disease. Kidney Int. 55, 2397\u20132406 (1999).","journal-title":"Kidney Int."},{"key":"13502_CR58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/jnci\/94.3.224","volume":"94","author":"MR Karagas","year":"2002","unstructured":"Karagas, M. R. et al. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J. Natl. Cancer Inst. 94, 224\u2013226 (2002).","journal-title":"J. Natl. Cancer Inst."},{"key":"13502_CR59","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrrheum.2014.144","volume":"10","author":"GC Hughes","year":"2014","unstructured":"Hughes, G. C. & Choubey, D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. Rheumatol. 10, 740\u2013751. https:\/\/doi.org\/10.1038\/nrrheum.2014.144 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"13502_CR60","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41598-024-75421-1","volume":"15","author":"Q Xu","year":"2025","unstructured":"Xu, Q. et al. Data mining and analysis of adverse events of Vedolizumab based on the FAERS database. Sci. Rep. 15, 278. https:\/\/doi.org\/10.1038\/s41598-024-75421-1 (2025).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13502-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:36:30Z","timestamp":1757356590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13502-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13502-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28529"}}